Scarica l'app Stockscreener
0.2919
6.77%
-0.0212
Dopo l'orario di chiusura:
.30
0.0081
+2.77%
Genprex Inc Borsa (GNPX) Ultime notizie
Genprex Enters $12.5M Stock Purchase Agreement - TipRanks
Genprex (GNPX) Announces Plan to Sell 15 Million Shares | GNPX Stock News - GuruFocus
Genprex Files for Resale of 15 Million Shares - marketscreener.com
genprex regains nasdaq compliance but faces bid price challenge By Investing.com - Investing.com South Africa
genprex regains nasdaq compliance but faces bid price challenge - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - mx.advfn.com
Genprex (NASDAQ:GNPX) Shares Down 2.8% – Should You Sell? - Defense World
Genprex to Participate at BIO 2025 International Convention - BioSpace
Genprex to Participate at BIO 2025 International Convention | GN - GuruFocus
Genprex to Participate at BIO 2025 International Convention | GNPX Stock News - GuruFocus
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Nasdaq
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting | GNPX Stock News - GuruFocus
Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus
What Can Genprex Inc (NASDAQ: GNPX) Expect In 2025? - Stocksregister
WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus
Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World
Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech
Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex Announces Research Agreement for Diabetes Therapy - TipRanks
Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus
Genprex Secures Exclusive Patent License for Reqorsa - TipRanks
Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire
Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN
Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - SelectScience
Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister
Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus
Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView
Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus
Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex's Revolutionary Gene Therapy Defeats Drug-Resistant Lung Cancer in Latest Trial Data - Stock Titan
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve
Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus
Taking the lead: Genprex Inc (GNPX) - Sete News
Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com
Revolutionary Gene Therapy Could Transform Diabetes Treatment: New Primate Study Reveals Promising Results - Stock Titan
Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus
Indo-Asian News Service - Indo-Asian News Service (IANS)
Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa
Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia
Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com
Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):